Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

This is a prospective, multicenter, multi-arm, non-randomized, open-label clinical trial to evaluate the efficacy and safety of neoadjuvant intense endocrine therapy for high-risk or locally advanced prostate cancer.

Trial Details

NCT ID

NCT05406999

Phase

PHASE2

Sponsor

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Status

RECRUITING

Cancer Type

Castration-Resistant (CRPC) Prostate Cancer

Interventions

ADT
Abiraterone Acetate
Prednisolone tablets
Enzalutamide
Apalutamide
Darotamide

Locations (sample)

Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

All patients must have been histologically diagnosed of prostate cancer and must be eligible for radical prostatectomy.
All patients must undergo thorough tumor staging and meet one of the following criteria: a) multi-parameter MRI or PSMA PET/CT shows clinical stagi…
Eastern Cooperative Oncology Group (ECOG) physical condition score ≤ 1.
Patients must have adequate hematologic function, hepatic function, renal function and cardiac function.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Castration-Resistant (CRPC) Prostate Cancer Trials on Trialify →